It’s estimated that 90% of retail investors lose money. We help you beat those odds with concise research, education and more. Click here to see our offerings.
- A late clinical-stage biotech company developing/commercializing oral biological therapeutics to treat rare and severe metabolic and kidney disorders
- Lead asset reloxaliase= in a pivotal P3 clinical program for the treatment of enteric hyperoxaluria (a metabolic disorder commonly associated with kidney stones, chronic kidney disease, and other serious kidney disorders)
- Second asset ALLN-346= entering P2 of development to treat hyperuricemia in the setting of gout and advanced chronic kidney disease